Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ride the Tiger with CD -- Ignore unavailable to you. Want to Upgrade?

To: cessnastreet who wrote (259400)	5/23/2018 2:50:36 PM
From: Rocket Red	Read Replies (2) \| Respond to of 312821

ICO- one for the watch list -We review its oral formulation of amphotericin B (AmpB). iCo ... The functional cure represents a potentially disruptive holy grail in the $14bn iCo Therapeutics Inc.'s subsidiary, iCo Therapeutics Australia Pty. Ltd., has dosed the first patient in its phase 1 clinical study for oral Amphotericin B. "Dosing our first patient is a major milestone for iCo Therapeutics and the oral Amphotericin B program," stated Andrew Rae, president and chief executive officer of iCo Therapeutics. "We currently remain on track to complete dosing of patients in the phase 1 study by the end of Q2 2018 and expect this to be the first of several key milestones for the company during 2018." Michael Winlo, chief executive officer of Linear Clinical Research Ltd., stated: "By working closely with the iCo team, recruitment has proceeded on schedule and we are very pleased to announce the first subject was dosed today. We look forward to completing this study swiftly and bringing a new therapy to patients in need."